Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and... see more

TSX:ONC - Post Discussion

Oncolytics Biotech Inc > Pfizer invests in allogeneic CAR-T therapy company
View:
Post by Noteable on Jul 06, 2023 11:08am

Pfizer invests in allogeneic CAR-T therapy company

July 06, 2023 - Pfizer purchased 4.6 million shares of Caribou common stock at $5.33 per share in a deal that added up to $25 million and closed June 30.

"Durability is a widespread issue for allogeneic CAR-T developers. In an attempt to tackle CAR-T cell exhaustion and maintain high anti-tumor activity for a longer time, Caribou had removed the PD-1 receptors from its anti-CD19 candidate CB-010. However, last year’s results raise questions about the impact of the work to boost durability. 


The relapses overshadowed other, more encouraging aspects of the data, like the 100% complete response rate at the starting dose of 40 million CAR-T cells and no high-grade safety events. "

https://www.fiercebiotech.com/biotech/pfizer-pours-25m-equity-investment-caribous-cell-therapies

[ Dr. Richard Vile of the Mayo Clinic has demonstrated that CAR-T therapy + pelareorep followed by a pelareorep "boost" resulted in CAR=T durability that was determined a "cure" in the animal model ]
Comment by Noteable on Jul 06, 2023 11:15am
Furthermore, ONCY has received no government funding in the development of pelareorep, which serves to preclude any US government proposals to cap drugs which developed with federal funds, thus placing ONCY's pelareorep in an unrestricted pricing space that is favorable to any acquirer of ONCY. https://www.fiercepharma.com/pharma/sen-sanders-proposes-price-caps-drugs-which-were-developed ...more  
Comment by Noteable on Jul 06, 2023 11:17am
Should read: "... any US government proposals to cap drug prices for drugs developed with federal funds ..."
Comment by itntdf on Jul 06, 2023 2:24pm
but, could the government cap treatment costs if/when pela is combined with drugs which have been funded in some way by the government like gemcitabine or nab-pax?
Comment by Noteable on Jul 06, 2023 2:36pm
Nope. Paclitaxel is already a generic drug and combination with this generic will have no impact on pelareorep's pricing.
Comment by Noteable on Jul 06, 2023 2:48pm
Nor will pricing of pelareorep be impacted by any other drug, generic or not, given that ONCY has self-funded pelareorep's clinical development, or has been supported by a non-profit organization such as PanCan, which has worked to fund the National Cancer Institute.(NCI), rather than the reverse. https://pancan.org/research/increasing-pancreatic-cancer-research-funding/
Comment by itntdf on Jul 06, 2023 5:14pm
thanks
Comment by Noteable on Jul 06, 2023 11:22am
Dr. Richard Vile of the Mayo Clinic has demonstrated that CAR-T therapy + pelareorep followed by a pelareorep "boost" resulted in CAR-T durability that was determined a "cure" in the treatment of solid tumors.
Comment by Noteable on Jul 11, 2023 11:40am
Pfizer purchased 4.6 million shares of Caribou common stock at $5.33 per share in a deal that added up to $25 million and closed June 30.
Comment by Azzak34 on Jul 11, 2023 12:02pm
This made me think too! 
Comment by Noteable on Jul 14, 2023 9:33am
July 14, 2023 - Caribou's gene-edited allogeneic CAR-T therapy resulted in a 44% complete response at 6 months in lympho-depleted conditioned lymphoma patients . "... a familiar problem appears in this data that has led to questions in previous readouts: durability " " “I wish CAR-T was the magic bullet that led to disease remission for every patient for all time ...more  
Comment by askretka on Jul 15, 2023 5:33pm
Pfizer also has a 25% in off shelf CAR-T company Allogene Therapeutics  " Pfizer will hold a 25 percent ownership stake in Allogene Therapeutics https://www.pfizer.com/news/press-release/press-release-detail/pfizer_and_allogene_therapeutics_enter_into_asset_contribution_agreement_for_pfizer_s_allogeneic_car_t_immuno_oncology_portfolio
Comment by Noteable on Jul 30, 2023 11:29am
The addition of ONCY's pelareorep overcomes CAR-T exhaustion. [ Dr. Richard Vile of the Mayo Clinic has demonstrated that CAR-T therapy + pelareorep followed by a pelareorep "boost" resulted in CAR-T durability that was determined a "cure" in the animal model ]
Comment by Noteable on Jul 30, 2023 3:13pm
ONCY appears to be closely aligned with Pfizer's oncology acquisition and clinical development program given recent news on Pfizer's CD3 bispecific, ADC, CAR-T and current small molecule portfolio (PARP inhibitor), as several examples.  Consequently, ONCY's acquisition valuation is within the US$10 - US$15 Billion, while some would suggest considerable higher, and that is quite ...more  
Comment by fox7mf on Jul 30, 2023 3:28pm
Perhaps somewhere between $15b-$25b would be more appropriate for all that Oncy & Pela can bring to a BP's bottom line for years to come. My opinion. 
Comment by Buckhenry on Jul 30, 2023 3:50pm
Perhaps... could... maybe... if.... seems like every post from the dreamers section starts with one of these words. I put some numbers on dog biscuits  and the first one my dog ate is what I think the company will be sold for. I figure it's as valid as the othe bs I read here. 
Comment by Azzak34 on Jul 30, 2023 4:01pm
Yeah, so.... which one did it eat? 
Comment by Noteable on Jul 30, 2023 5:27pm
Pfizer invested in Caribou with the point being that Pfizer is covering all bases. This perhaps in the use of CAR-T in solid tumors, as it has had success with its CD3-BCMA bispecific anti-body in multiple myeloma, a liquid cancer.
Comment by Noteable on Oct 05, 2023 6:00pm
ONCY appears to be closely aligned with Pfizer's oncology acquisition and clinical development program given recent news on Pfizer's CD3 bispecific, ADC, CAR-T and current small molecule portfolio (PARP inhibitor), as several examples. 
Comment by jh1970 on Oct 05, 2023 8:42pm
Pfizer invested $25mil at $5.33 per share . After this investment Caribou did financing for $125mil at $6.5 per share which make sense. Why ONC did financing at very low price before partnership agreement not after? Are ONC having problem to have partner ? To many difficult questions .
Comment by fox7mf on Oct 05, 2023 8:57pm
PFE did blow off Oncy after that sham of the 90 day exclusivity on Bracelet data expired.
Comment by Noteable on Oct 05, 2023 9:02pm
Pfizer is still in the game with ONCY's pelareorep aligned with multiple Pfizer cancer franchises.
Comment by Noteable on Oct 05, 2023 9:14pm
Oncy's capital raise was to capitalize on the opportunity presented by PanCan to run a Phase 3 metastatic pancreatic cancer trial under their Precision Promise program. With ONCY correspondingly applying for an ACCELERATED APPROVAL, further leverage on a negotiated acquisition price would putatively result.
Comment by jh1970 on Oct 05, 2023 9:32pm
Why offering at $2.25 not much higher at $3. We still do not know who bought them. Maybe to cover shorts? To many difficult questions.
Comment by Lesalpes29 on Oct 06, 2023 6:59am
Money is always good! But again the last PP was a cheap one and since then the SP is stagnant. ONCY seems to always negociate terms in so so position. Now we hope the ph3 in PANC will show good results. A buyout in billions is still a dream or a good running gag! Have great long weekend,
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities